Tuesday, May 17, 2022
News for Retirees


ADC Therapeutics Receives Everlasting J-Code for ZYNLONTA® (J9359) from U.S. Facilities for Medicare & Medicaid Providers

LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology firm enhancing the lives of these affected by most cancers…

By Staff , in Medicare , at April 4, 2022


LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology firm enhancing the lives of these affected by most cancers with its next-generation, focused antibody drug conjugates (ADCs) for sufferers with hematologic malignancies and stable tumors, introduced immediately {that a} everlasting J-code, J9359, has been issued for ZYNLONTA® by the U.S. Facilities for Medicare & Medicaid Providers (CMS) efficient as of April 1, 2022.

“As we develop our U.S. ZYNLONTA enterprise from the tutorial establishments and early adopting neighborhood networks into an rising variety of neighborhood accounts, our everlasting J-code will provide accounts predictability by way of reimbursement,” mentioned Jennifer Herron, Chief Industrial Officer of ADC Therapeutics. “The everlasting J-code for ZYNLONTA will enhance entry for sufferers and can simplify the reimbursement course of for treating physicians and their employees.”

J-codes are everlasting reimbursement codes utilized by business insurance policy, Medicare, Medicare Benefit, and different authorities payers for Medicare Half B injectable medication like ZYNLONTA which are administered by a doctor. Claims submission and documentation are simplified with a everlasting J-code, facilitating and streamlining the billing and reimbursement course of.

The everlasting J-code for ZYNLONTA, J9359 (Injection, loncastuximab tesirine-lpyl, 0.075 mg), took impact April 1, 2022. The everlasting J-code can be revealed on-line on the CMS web site right here.

About ZYNLONTA® (loncastuximab tesirine-lpyl)

ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). As soon as sure to a CD19-expressing cell, ZYNLONTA is internalized by the cell, the place enzymes launch a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining much less seen to DNA restore mechanisms. This in the end leads to cell cycle arrest and tumor cell demise.

The U.S. Meals and Drug Administration (FDA) has accredited ZYNLONTA (loncastuximab tesirine-lpyl) for the remedy of grownup sufferers with relapsed or refractory (r/r) giant B-cell lymphoma after two or extra strains of systemic remedy, together with DLBCL not in any other case specified, DLBCL arising from low-grade lymphoma and likewise high-grade B-cell lymphoma. The trial included a broad spectrum of closely pre-treated sufferers (median three prior strains of remedy) with difficult-to-treat illness, together with sufferers who didn’t reply to first-line remedy, sufferers refractory to all prior strains of remedy, sufferers with double/triple hit genetics and sufferers who had stem cell transplant and CAR-T remedy previous to their remedy with ZYNLONTA. This indication is accredited by the FDA below accelerated approval primarily based on total response fee and continued approval for this indication could also be contingent upon verification and outline of medical profit in a confirmatory trial.

ZYNLONTA can be being evaluated as a therapeutic choice together research in different B-cell malignancies and earlier strains of remedy.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology firm enhancing the lives of these affected by most cancers with its next-generation, focused antibody drug conjugates (ADCs). The Firm is advancing its proprietary PBD-based ADC know-how to remodel the remedy paradigm for sufferers with hematologic malignancies and stable tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) is accredited by the FDA for the remedy of relapsed or refractory diffuse giant B-cell lymphoma after two or extra strains of systemic remedy. ZYNLONTA can be in improvement together with different brokers. Cami (camidanlumab tesirine) is being evaluated in a pivotal Section 2 trial for relapsed or refractory Hodgkin lymphoma and in a Section 1b medical trial for varied superior stable tumors. Along with ZYNLONTA and Cami, ADC Therapeutics has a number of ADCs in ongoing medical and preclinical improvement.

ADC Therapeutics relies in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Space and New Jersey. For extra data, please go to https://adctherapeutics.com/ and comply with the Firm on Twitter and LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.





Source link

Skip to content